Search for


TEXT SIZE

search for



CrossRef (0)
Annual Report of Korean Association of External Quality Assessment Service on Histocompatibility Testing (2018)
J Lab Med Qual Assur 2019;41:130-152
Published online September 30, 2019
© 2019 Korean Association of External Quality Assessment Service.

Eun-Suk Kang

Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Correspondence to: Eun-Suk Kang
Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea
Tel: +82-2-3410-2703 Fax: +82-2-3410-2719 E-mail: eskang@skku.edu
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
 Abstract

Here, we report the results of the first histocompatibility proficiency testing (PT) performed by the Korean Association of External Quality Assessment Service in 2018. The directly prepared PT specimens of whole blood, sera, and mononuclear cell suspensions were distributed to participants biannually. The number of participants was comparable to that in the previous external PT program, and the response rate was 88%–100%. The accuracy rates for human leukocyte antigen (HLA) A, B, C, DR, and DQ low and high resolution typing were 100%/100%, 100%/98%, 100%/99%, and 99%/98%, respectively; HLA-B27 typing, 99.1%; T cell and B cell crossmatching, 3.1% and 6.0%, respectively; and HLA antibody screening and identification, 100% and 100%, respectively. The results of HLA crossmatching were not reported from four participants due to poor cell viability. Further improvements of the specimen delivery process, grading criteria for crossmatching, and format of participant summary are warranted.

Keywords : Histocompatibility, Proficiency testing, Korean Association of External Quality Assessment Service
꽌濡

議곗쭅쟻빀꽦(histocompatibility)寃궗뒗 꽦怨듭쟻씤 씠떇쓣 쐞빐꽌뒗 븘닔쟻씤 寃궗씠떎. 議곗쭅쟻빀꽦빆썝(human leukocyte antigen, HLA) 삉뒗 二쇱“吏곷났빀泥(major histocompatibility complex) 삎蹂꾧궗(HLA typing)뒗 옣湲 諛 議고삁紐⑥꽭룷 씠떇 쟾 理쒖쟻쓽 怨듭뿬옄瑜 꽑蹂꾪븯怨, HLA 援먯감떆뿕(HLA crossmatching) 諛 HLA 빆泥닿궗(HLA antibody testing)瑜 넻빐 遺쟻빀 怨듭뿬옄瑜 諛곗젣븯怨 씠떇 썑 寃쎄낵瑜 삁痢≫븯뒗 뜲 以묒슂븳 젙蹂대 젣怨듯븳떎. 씪遺 듅젙 HLA삎 吏덈퀝뿰愿꽦씠 넂븘 듅젙 吏덈퀝쓣 吏꾨떒븯뒗 寃껋뿉 씠슜맂떎. 듅엳 援궡뿉꽌 씠떇쓣 쐞븳 씤 怨듭뿬옄쓽 留ㅼ묶 吏덈퀝愿由щ낯遺 옣湲곗씠떇愿由ъ꽱(Korean Network for Organ Sharing)쓽 以묒븰솕맂 젙蹂댁떆뒪뀥쓣 넻빐 씠猷⑥뼱吏怨 엳쑝硫 씠븣 뿬윭 떎瑜멸린愿뿉꽌 떆뻾썑 엯젰븳 寃궗寃곌낵瑜 諛뷀깢쑝濡 꽑젙븯寃 맂떎. 洹몃윭誘濡 湲곌 媛 HLA寃궗쓽 몴以솕 샇솚꽦 留ㅼ슦 以묒슂븯떎.

援궡뿉꽌뒗 1993뀈 꽕臾몄“궗瑜 넻빐 18媛 湲곌씠 HLA寃궗瑜 떆뻾븯怨 엳쓬쓣 솗씤븳 씠썑 吏냽쟻쑝濡 寃궗떆뻾湲곌씠 利앷릺뼱 솕떎[1]. 援궡 쇅遺젙룄愿由ы봽濡쒓렇옩 Park 벑[2]씠 援궡 봽濡쒓렇옩쓣 媛쒕컻븯怨좎옄 1996뀈遺꽣 1998뀈뿉 嫄몄퀜 援媛뿰援щ퉬 湲곕컲쓽 떆踰붿궗뾽쑝濡 떆옉븯쑝硫, 2000뀈룄遺꽣뒗 븳吏꾨떒寃궗쓽븰쉶 젙룄愿由щ텇怨 궗뾽쓽 씪솚쑝濡 蹂멸꺽쟻쑝濡 吏꾪뻾릺뼱 2017뀈룄源뚯 吏냽릺뿀떎. 븳엫긽寃궗젙룄愿由ы삊쉶뒗 2017뀈 援媛 吏 愿由щ즺 궛젙뿉 뵲瑜 湲곌룊媛媛 룄엯맖뿉 諛쒕쭪異붿뼱 李⑥꽭떊鍮숇룄議곗궗궗뾽쓽 씪솚쑝濡 李⑥꽭쟾궛떆뒪뀥쓽 룄엯怨 뜑遺덉뼱 遺꾩빞 諛 빆紐⑹쓽 솗瑜 異붿쭊븯뿬 솕쑝硫 2018뀈 議곗쭅쟻빀꽦寃궗 쇅遺젙룄愿由ы봽濡쒓렇옩쓣 룄엯븯떎. 뵲씪꽌 18뀈媛 吏냽빐삩 븳吏꾨떒寃궗쓽븰쉶 젙룄愿由щ텇怨쇱쓽 議곗쭅쟻빀꽦 쇅遺젙룄愿由ы봽濡쒓렇옩 以묐떒릺怨 쁽옱쓽 봽濡쒓렇옩쑝濡 泥대릺뿀떎.

議곗쭅쟻빀꽦寃궗봽濡쒓렇옩 吏꾨떒硫댁뿭븰 遺꾨쪟 궡 以묐텇瑜섏뿉 빐떦븯硫 냼遺꾨쪟뿉 湲곗〈쓽 쇅遺젙룄愿由ы봽濡쒓렇옩怨 룞씪븯寃 議곗쭅쟻빀꽦 삎蹂꾧궗(HLA typing), 듅닔議곗쭅쟻빀꽦 삎蹂꾧궗(HLA-B27 typing), 議곗쭅쟻빀꽦 援먯감떆뿕寃궗(HLA crossmatching), 洹몃━怨 議곗쭅쟻빀꽦 빆泥닿궗(HLA antibody testing) 빆紐⑹쓣 룷븿븯硫 뿰 2쉶뿉 嫄몄퀜 吏꾪뻾릺뿀떎.

씠뿉 옄뒗 2018뀈 븳엫긽寃궗젙룄愿由ы삊쉶뿉꽌 떆뻾맂 泥 議곗쭅쟻빀꽦寃궗 떊鍮숇룄議곗궗 寃곌낵 궡슜쓣 蹂닿퀬븯怨좎옄 븳떎.

옱猷 諛 諛⑸쾿

1. 議곗궗빆紐

議곗쭅쟻빀꽦寃궗봽濡쒓렇옩 뿰 2쉶뿉 嫄몄퀜 HLA 삎蹂꾧궗, HLA-B27 寃궗, HLA 援먯감떆뿕, 洹몃━怨 HLA 빆泥 꽑蹂(screening)怨 룞젙(identification) 寃궗 珥 5媛 빆紐⑹뿉 빐 떆뻾릺뿀떎. 떊꽑븳 꽭룷濡 諛곗넚릺뼱빞 븯뒗 듅꽦긽 24-72떆媛꾩뿉 寃泥닿 쟾떖릺룄濡 떊냽 삁빟諛곗넚떆뒪뀥쓣 솢슜븯怨, 떎삩긽깭뿉꽌 꽭룷 떊꽑룄瑜 蹂댁쬆븯湲 쐞븯뿬 쇅遺 湲곗삩씠 넂吏 븡 4썡 泥レ㎏ 二쇱 10썡 몮吏 二 썡슂씪뿉 諛쒖넚븯떎.

2. 쇅遺떊鍮숇룄議곗궗슜 젙룄愿由щЪ吏

寃泥댁쓽 젣議곕뒗 옄媛젣議곕Ъ吏 媛쒕컻 슜뿭뿰援щ 留≪ 궪꽦꽌슱蹂묒썝뿉꽌 닔뻾븯떎. 寃泥 젣議곕 쐞븳 삁븸쓣 솗蹂댄븯湲 쐞븯뿬 뿰援ъ쑄由ъ쐞썝쉶(Institutional Review Board)쓽 떖쓽瑜 뱷븯쑝硫 怨듭臾몄쓣 넻빐 옄썝옄瑜 紐⑥쭛븯떎. 옄썝옄뒗 삁븸怨듭뿬옄 꽑蹂꾧린以뿉 뵲씪 쟻빀꽦쓣 솗씤븯떎. 옄媛젣議곕맂 臾쇱쭏 遺꾩< 諛 씪踰⑤쭅쓣 留덉튇 썑 븳엫긽寃궗젙룄愿由ы삊쉶濡 利됱떆 슫諛섎릺뼱 룷옣맂 썑 媛 李몄뿬湲곌쑝濡 떦씪 諛쒖넚릺뿀떎. 援궡 듅湲됱슦렪쓣 씠슜븯뿬 삁泥 깋옣, 꽭룷뒗 떎삩긽깭뿉꽌 諛곗넚릺뿀쑝硫 諛쒖넚 썑 24-48떆媛 궡뿉 寃궗떎뿉 룄李⑸맆 닔 엳룄濡 븯떎. 젣二쇰룄쓽 寃쎌슦뿉뒗 빆怨듭슦렪쓣 씠슜븯뿬 72떆媛 궡뿉 룄李⑸맆 닔 엳룄濡 븯떎.

1) HLA 삎蹂꾧궗 諛 HLA-B27삎 寃궗슜 쟾삁 젣議

옄썝옄뱾쓣 긽쑝濡 誘몃━ HLA 삎蹂꾧궗瑜 떆뻾븯뿬 援먯감떆뿕뿉꽌룄 솢슜븷 닔 엳뒗 HLA 삎怨 HLA-B27 뼇꽦 寃泥대 솗蹂댄븯떎. 諛쒖넚 떦씪 꽑蹂꾪븳 옄썝옄뱾濡쒕꽣 ethylenediaminetetraacetic acid 쟾삁쓣 梨꾩쭛븳 썑 떆뿕愿떦 1 mL뵫 利됱떆 遺꾩<븯떎. 쉶李⑤떦 媛곴컖 2媛쒖뵫쓽 寃泥대 젣議고븯떎.

2) HLA 援먯감떆뿕슜 떒빑援 遺쑀븸 젣議

援먯감떆뿕뿉꽌 쟻젅븳 諛섏쓳쓣 蹂댁씠뒗 HLA 삎쓣 媛吏 옄썝옄濡쒕꽣 諛쒖넚 떦씪 삁븸遺꾨컲닠쓣 넻빐 븘슂븳 닔쓽 떒빑援щ 梨꾩쭛븯떎. 梨꾩쭛 利됱떆 0.5-1×107/mL쓽 냽룄媛 릺룄濡 옄媛삁옣쑝濡 씗꽍븳 썑 떆뿕愿떦 1 mL뵫 遺꾩<븯떎. 쉶李⑤떦 媛곴컖 2媛쒖뵫쓽 寃泥대 젣議고븯떎.

3) HLA 援먯감떆뿕 諛 빆泥대룞젙슜 삁泥 젣議

떊옣씠떇 湲 以 떒씪빆썝삎 鍮꾨뱶룞젙(single antigen bead identification)寃궗瑜 넻빐 빆썝 듅씠꽦씠 諛앺吏 솚옄濡쒕꽣 꽌硫대룞쓽꽌瑜 쉷뱷븳 썑 빟 100 mL쓽 쟾삁쓣 梨꾩쭛븯떎. 梨꾩쭛 쟾 떞떦 엫긽쓽濡쒕꽣 솚옄 긽깭뿉 븳 옄臾몄쓣 援ы븯쑝硫 긽깭뿉 뵲씪 븳踰덉뿉 100 mL 삉뒗 2李⑥뿉 굹늻뼱 珥 100 mL瑜 뿄삁떎뿉꽌 梨꾩쭛븯떎. 빟 2떆媛 諛⑹튂븯뿬 異⑸텇븳 삁븸쓳怨좉 吏꾪뻾맂 썑 3,000 rpm뿉꽌 15遺꾧컙 썝떖遺꾨━ 썑 삁泥쓣 쉶닔븯떎. 삁泥 0.2 mm 븘꽣瑜 궗슜븯뿬 泥섎━ 썑 –70°C뿉 깋룞蹂닿븯떎. 諛쒖넚 떦씪 빐룞븯뿬 떎떆 븳踰 썝떖遺꾨━ 썑 긽痢듭븸쓣 떆뿕愿떦 빟 500 L뵫 遺꾩<븯떎. 쉶李⑤떦 媛곴컖 2媛쒖뵫쓽 寃泥대 젣議고븯떎.

3. 寃곌낵 뙋젙 諛 遺꾩꽍

寃곌낵뒗 李⑥꽭떊鍮숇룄궗뾽 솃럹씠吏뿉 엯젰븯룄濡 븯怨, 엯젰湲곌컙 諛쒖넚 썑 2二쇱뿉 醫낅즺븯떎. 씠썑 엯젰寃곌낵뿉 븳 뜲씠꽣 삤瑜섎 寃利앺븳 썑 넻怨꾨텇꽍쓣 떆뻾븯떎. 紐⑤뱺 빆紐⑹ 젙꽦寃궗뿉 以븯뿬 뙋젙븯쑝硫 湲곕寃곌낵(intended response)뒗 떊猶고븷 留뚰븳 젙떟씠 엳뒗 寃쎌슦 洹몃젃吏 븡 寃쎌슦뿉뒗 蹂닿퀬븳 湲곌뿉꽌 80% 씠긽쓽 씪移섎 蹂댁씠뒗 寃곌낵濡 븯떎. 떒, HLA 援먯감떆뿕쓽 寃쎌슦 誘쇨컧룄媛 떎瑜 몢 媛吏 씠긽쓽 寃궗踰뺤쓣 諛섎뱶떆 떆뻾븯룄濡 沅뚭퀬븯怨 엳뒗 諛 誘쇨컧룄媛 넂 寃궗뿉꽌 80% 씠긽쓽 씪移섎 蹂댁씠吏 븡뒗 寃쎌슦 븯쐞寃궗쓽 寃곌낵뒗 Code 505濡 湲곗닠븯怨 뙋젙 젣쇅븯떎. HLA 援먯감떆뿕쓽 諛섏젙웾 寃곌낵 HLA 빆泥 빆썝꽦 룞젙 寃곌낵뒗 蹂꾨룄濡 뙋젙븯吏 븡븯떎.

寃곌낵

1.떊鍮숇룄議곗궗궗뾽 李몄뿬湲곌 쁽솴

媛 빆紐⑸퀎濡 2018뀈룄 떊鍮숇룄議곗궗뿉 李몄뿬븳 湲곌 닔 諛 쉶떊쑉 1李⑥뿉꽌뒗 100%쓽 쉶떊쑉쓣 蹂댁쑝굹 2李⑥뿉꽌뒗 HLA 援먯감떆뿕뿉꽌 T꽭룷 B꽭룷 媛곴컖 1湲곌怨 4湲곌 洹몃━怨 HLA 빆泥 꽑蹂꾧궗뿉꽌 1湲곌씠 쉶떊븯吏 븡븘 98%, 88% 洹몃━怨 95%쓽 쉶떊쑉쓣 蹂댁쑝硫 洹 쇅 빆紐⑹뿉꽌뒗 100%떎(Table 1).

Table 1 . Participating laboratories and response rates of the histocompatibility program.

 Test items1st2nd
HLA typing
 Low resolution100 (37/37)100 (37/37)
 Low and high resolution100 (65/65)100 (67/67)
HLA crossmatching
 T cell100 (48/48)98 (47/48)
 B cell100 (31/31)88 (29/33)
HLA antibody
 Screening100 (20/20)95 (19/20)
 Identification100 (22/22)100 (22/22)
HLA-B27 typing100 (56/56)100 (60/60)

Values are presented as % (number of participating laboratories)..

Abbreviation: HLA, human leukocyte antigen..


2. 議곗쭅쟻빀꽦 삎蹂꾧궗

李몄뿬븳 紐⑤뱺 湲곌씠 DNA 삎蹂꾧궗뿉 湲곕컲븳 寃곌낵瑜 蹂닿퀬븯떎. 빐긽룄 삎蹂꾧궗쓽 寃쎌슦 sequence specific oligonucleotide probe reverse (rSSOP) sequence specific primers (SSP)媛 媛옣 꼸由 궗슜릺뒗 諛⑸쾿씠뿀떎. 怨좏빐긽룄 삎蹂꾧궗쓽 寃쎌슦뿉뒗 sequence-based typing씠 떎닔瑜 李⑥븯쑝굹 3湲곌 洹 쇅 諛⑸쾿쓣 궗슜븯뒗 寃껋쑝濡 蹂닿퀬븯怨 븳 湲곌 rSSOP踰뺤쑝濡 怨좏빐긽룄寃궗瑜 떆뻾븳 寃껋쑝濡 蹂닿퀬븯떎(Table 2). 2018뀈룄 諛쒖넚맂 珥 4媛쒖쓽 臾쇱쭏뿉 븳 class I怨 class II뿉 븳 蹂닿퀬 寃곌낵뒗 Table 3Table 4 媛숇떎. HLA-A HLA-B뿉 븳 빐긽룄 怨좏빐긽룄 寃곌낵뿉 븳 젙떟瑜좎 紐⑤몢 100% (264/264, 114/114)떎. 洹몃윭굹 HLA-C뿉 븳 젙떟瑜좎 빐긽룄 寃곌낵뿉꽌뒗 100% (162/162)쑝굹 怨좏빐긽룄 寃곌낵뿉 빐꽌뒗 98% (108/110)瑜 蹂댁뒗뜲, 삎蹂 寃곌낵뒗 湲곕寃곌낵뿉 遺빀븯쑝굹 몴湲곕쾿긽 쑀쟾옄醫뚮 삁泥삎怨 媛숈 Cw濡 몴湲고븯뿬 옒紐삳맂 슜뼱몴湲곕쾿(nomenclature)쑝濡 蹂닿퀬瑜 븯떎. 듅엳 HLA-C쓽 寃쎌슦 삁泥삎씠 湲곕寃곌낵뿉 뼱湲뗫굹뒗 寃쎌슦媛 10嫄(6%, 10/166) 엳뿀뒗뜲 옒紐삳맂 삁泥삎쓣 蹂닿퀬븳 湲곌 1湲곌(0.6%)씠뿀쑝硫 굹癒몄 9湲곌(5.4%)쓽 寃쎌슦뿉뒗 broad specificity瑜 蹂닿퀬븳 寃쎌슦떎. 씠뒗 씪遺 SSP 떆빟뿉꽌 Cw9 Cw10쓣 援щ텇븯吏 紐삵븯뒗 寃쎌슦媛 엳뼱 씠뿉 빐떦맆 寃껋쑝濡 깮媛곷릺뿀떎(Table 3).

Table 2 . Methods of HLA typing for different loci.

 Resolution/methods/manufacturers1st2nd


HLA-A, -B, -DRB1HLA-CHLA-DQHLA-A, -B, -DRB1HLA-CHLA-DQ
Low resolution generic type653929674234
 Sequence-based typing1313814149
  Biowithus Inc.773884
  GenDx554554
  One Lambda111111
 Sequence-specific oligonucleotide probe reverse261316291518
  Fujirebio Inc.752972
  Immucor Lifecodes125912510
  One Lambda735836
 Sequence-specific primers21931994
  Biosewoom1142932
  One Lambda10511062
 Other methods542543
  Biosewoom112221
  Biowithus Inc.11---1
  Others32-321
High resolution allelic type282714292816
 Sequence-based typing242411252512
  Biowithus Inc.1414515156
  GenDx885885
  One Lambda221221
 Sequence-specific oligonucleotide probe reverse1--1-1
  Fujirebio Inc.1--1--
  Immucor Lifecodes----1
 Other methods333333
  Biosewoom221221
  Biowithus Inc.112--1
  Others---111

Abbreviation: HLA, human leukocyte antigen..

The instruments were from the following companies: Biowithus Inc. (Seoul, Korea); GenDx (Utrecht, The Netherlands); One Lambda (Canoga Park, CA, USA); Fujirebio Inc. (Tokyo, Japan); Immucor Lifecodes (Stamford, CT, USA); and Biosewoom (Seoul, Korea)..


Table 3 . Results of human leukocyte antigen class I typing.

TrialSpecimen Type ANo. of labs BNo. of labs CNo. of labs
1stIHL-18-01Generic typeA*11/A*2465B*40/B*4049C*03/C*0326
B*40/blank16C*03/blank13
Allelic typeA*11:01/A*24:0222B*40:01/B*40:0622C*03:03/C*03:0417
A*11:01:01G/A*24:02:01G3B*40:01:01G/B*40:06:01G3C*03:03:01G/C*03:04:01:01G3
A*11:01G/A*24:02G3B*40:01G/B*40:06G3C*03:03G/C*03:041
C*03:03G/C*03:04G3
C*03:04/C*03:032
Cw*03:03/Cw*03:041
Serological equivalentA11/A2463B60/B6164Cw3/Blank2
Cw3/Cw31
Cw3/Cw91
Cw9/Cw1036
IHL-18-02Generic typeA*02/A*1165B*35/B*5165C*03/C*1439
Allelic typeA*02:01/A*11:0122B*35:01/B*51:0121C*03:03/C*14:0219
A*02:01:01G/A*11:01:01G3B*35:01:01G/B*51:01:01G3C*03:03:01G/C*14:02:01G3
A*02:01G/A*11:01G3B*35:01G/B*51:011C*03:03G/C*14:021
B*35:01G/B*51:01G3C*03:03G/C*14:02G3
Cw*03:03/Cw*14:021
Serological equivalentA2/A1163B35/B5164Cw1/Cw91
Cw3/blank1
Cw3/Cw141
Cw3/other1
Cw9/blank18
Cw9/Cw147
Cw9/other11
2ndIHL-18-03Generic typeA*01/A*0267B*37/B*5167C*06/C*1442
Allelic typeA*01:01/A*02:0623B*37:01/B*51:0123C*06:02/C*14:0221
A*01:01G/A*02:06G6B*37:01G/B*51:01G6C*06:02G/C*14:021
C*06:02G/C*14:02G6
Serological equivalentA1/A266B37/B5166Cw6/blank22
Cw6/Cw148
Cw6/other13
IHL-18-04Generic typeA*02/A*2467B*13/B*5967C*01/C*0342
Allelic typeA*02:01/A*24:0223B*13:01/B*59:0123C*01:02/C*03:0422
A*02:01G/A*24:02G6B*13:01G/B*59:01G6C*01:02G/C*03:04G6
Serological equivalentA2/A2466B13/B5966Cw1/Cw1041
Cw1/Cw32

Bold letter indicates the results which are not compliant with the intended responses..


Table 4 . Results of human leukocyte antigen class II typing.

 TrialSpecimen Type DRNo. of labs (%) DQNo. of labs (%)
1stIHL-18-01Generic typeDRB1*04/DRB1*0865DQB1*03/DQB1*0628
DQB1*01/DQB1*031
Allelic typeDRB1*04:03/DRB1*08:0321DQB1*03:02/DQB1*06:0110
DRB1*04:03:01G/DRB1*08:03:02G3DQB1*03:02G/DQB1*06:01G2
DRB1*04:03G/DRB1*08:03G3DQB1*06:01/DQB1*03:021
DR*04:03/DR*08:031DQ*03:02/DQ*06:011
Serological equivalentDR4/DR863DQ6/DQ830
IHL-18-02Generic typeDRB1*11/DRB1*1265DQB1*03/blank16
DQB1*03/DQB1*0313
Allelic typeDRB1*11:01/DRB1*12:0115DQB1*03:01/DQB1*99:997
DRB1*11:01G/DRB1*12:01G4DQB1*03:01/DQB1*03:013
DRB1*11:01/DRB1*12:01G3DQB1*03:01G/DQB1*99:992
DRB1*11:01:01G/DRB1*12:01:01G3DQB1*03:01/-1
DRB1*11:01/DRB1*12:01/101DQ*03:01/-1
DRB1*11:01/DRB1*12:01:01G1
DR*11:01/DR*12:011
Serological equivalentDR11/DR1263DQ7/blank17
DQ7/DQ713
2ndIHL-18-03Generic typeDRB1*09/DRB1*1067DQB1*03/DQB1*0528
DQB1*05/DQB1*036
Allelic typeDRB1*09:01/DRB1*10:0124DQB1*03:03/DQB1*05:0110
DRB1*09:01G/DRB1*10:01G5DQB1*05:01/DQB1*03:035
DQB1*03:03G/DQB1*05:01G1
Serological equivalentDR9/DR1066DQ9/DQ526
DQ5/DQ99
IHL-18-04Generic typeDRB1*04/DRB1*1267DQB1*03/DQB1*0428
DQB1*04/DQB1*036
Allelic typeDRB1*04:05/DRB1*12:0119DQB1*03:01/DQB1*04:0110
DRB1*04:05G/DRB1*12:01G6DQB1*04:01/DQB1*03:015
DRB1*04:05/DRB1*12:01G4DQB1*03:01G/DQB1*04:01G1
Serological equivalentDR4/DR1266DQ7/DQ427
DQ4/DQ78

Bold letter indicates the results which are not compliant with the intended responses..


HLA-DR뿉 븳 빐긽룄 怨좏빐긽룄 寃곌낵뿉 븳 젙떟瑜좎 媛곴컖 100% (264/264) 99% (113/114)씠뿀떎. 븳 湲곌뿉꽌 怨좏빐긽 DR삎쓣 몴湲 떆 DRB1*11:01/DRB1*12:01씠 븘땶 DR*11:01/DR*12:01濡 옒紐삳맂 슜뼱몴湲곕쾿쑝濡 蹂닿퀬瑜 븯떎. HLA-DQ뿉 븳 빐긽룄 怨좏빐긽룄 寃곌낵뿉 븳 젙떟瑜좎 媛곴컖 99% (125/126) 98% (59/60)씠뿀떎. 빐긽룄뿉꽌 븳 湲곌씠 DQB1*06DQB1*01濡 蹂닿퀬븯쑝硫, 怨좏빐긽룄뿉꽌뒗 븳 湲곌씠 DQB1*03:01/-媛 븘땶 DQ*03:01/-濡 옒紐삳맂 슜뼱몴湲곕쾿쑝濡 蹂닿퀬瑜 븯떎(Table 4).

3. 듅듅닔議곗쭅쟻빀꽦 삎蹂꾧궗

媛뺤쭅꽦 泥숈닔뿼(ankylosing spondylitis)怨 愿젴꽦씠 엳뒗 HLA-B27삎 寃궗뒗 1李⑥뿉뒗 56湲곌, 2李⑥뿉뒗 60湲곌씠 李몄뿬븯떎. 媛 쉶李⑤떦 1媛쒖쓽 뼇꽦 臾쇱쭏怨 1媛쒖쓽 쓬꽦臾쇱쭏쓣 諛곗넚븯떎. 삁泥삎 諛 빐긽룄 닔以쓽 寃곌낵濡 뙋젙븯怨 엳뼱 쑀꽭룷遺꾩꽍踰(flow cytometry, FCM)怨 媛숈 꽭룷硫댁뿭븰쟻 諛⑸쾿怨 polymerase chain reaction (PCR)쓣 湲곕컲쑝濡 븳 遺꾩옄쑀쟾븰쟻 諛⑸쾿씠 궗슜릺怨 엳뿀떎(Table 5). 떎닔 긽뭹솕맂 떆빟쓣 궗슜븯怨 엳뿀쑝굹 옄泥 媛쒕컻븳 遺꾩옄쑀쟾븰쟻 寃궗踰뺤쑝濡 떆뻾븯怨 엳뒗 湲곌룄 1李⑥뿉꽌뒗 2湲곌, 2李⑥뿉꽌뒗 3湲곌 엳뿀떎. 젙떟瑜좎 1李⑥뿉꽌 98%濡 PCR踰뺤쑝濡 寃궗븳 1湲곌씠 쓬꽦寃곌낵瑜 뼇꽦쑝濡 蹂닿퀬븯쑝굹, 2李⑥뿉꽌뒗 100%떎.

Table 5 . Methods and results of HLA-B27 typing.

 Methods/manufacturers1st2nd


IB27-18-01IB27-18-02IB27-18-03IB27-18-04



PresentAbsentPresentAbsentPresentAbsent
Flow cytometry2222
 Becton Dickinson HLA-B27 kit1122
 Beckman Coulter Inc.11
Molecular1515115555
 BioCore HLA-B*27 PCR kit8888
 Bioneer AccuPower HLA-B27 Real-Time PCR kit5555
 Biosewoom HLA-B*27 PCR kit16161717
 Biosewoom Real-Q HLA-B*27 Detection kit11111111
 Biowithus HuGen HLA-B*27 PCR177188
 Infopia GeneFinder HLA-B*27 RealAmp kit2233
 Laboratory developed test2233
Other methods2233
 Others2233
 Total1555516060

Abbreviations: HLA, human leukocyte antigen; PCR, polymerase chain reaction..


4. 議곗쭅쟻빀꽦 援먯감떆뿕寃궗

媛 쉶李⑤떦 2媛쒖쓽 삁泥怨 2媛쒖쓽 떒빑援щ쑀븸쓣 諛곗넚븯뿬 4뙇뵫쓽 援먯감떆뿕쓣 떆뻾븯룄濡 븯쑝硫 珥 8뙇쓽 寃곌낵瑜 뼸뿀떎. 1李⑥뿉뒗 T꽭룷 援먯감떆뿕뿉뒗 珥 48湲곌씠, B꽭룷 援먯감떆뿕뿉뒗 珥 31湲곌씠 李몄뿬븯떎. T꽭룷 援먯감떆뿕쓽 寃쎌슦 誘쇨컧룄媛 떎瑜 몢 媛吏 씠긽쓽 寃궗踰뺤쓣 諛섎뱶떆 떆뻾븯룄濡 沅뚭퀬븯怨 엳떎. 쟾泥댁쟻쑝濡 29湲곌씠 T꽭룷-蹂댁껜留ㅺ컻꽭룷룆꽦踰(T cell-complement dependent cytotoxicity)-Direct踰(T-CDC-Direct踰), T-CDC-anti-human globulin踰(T-CDC-AHG踰)怨 T-flow cytometry踰(T-FCM踰)쓣 紐⑤몢 떆뻾븯怨, 14湲곌씠 T-CDC-Direct踰뺢낵 T-CDC-AHG踰뺤쓣 떆뻾 蹂닿퀬븯떎. 媛곴컖 2湲곌뵫 T-CDC-Direct踰뺢낵 T-FCM踰뺤쓣 洹몃━怨 T-CDC-AHG踰뺢낵 T-FCM踰뺤쓣 떆뻾븯쑝硫, 1湲곌 T-FCM踰 寃곌낵留뚯쓣 蹂닿퀬븯떎. B꽭룷 援먯감떆뿕쓽 寃쎌슦 11湲곌뿉꽌 B-CDC-Direct踰뺢낵 B-FCM踰 寃곌낵瑜 紐⑤몢, 8湲곌뿉꽌뒗 B-CDC-Direct踰 寃곌낵留뚯쓣 洹몃━怨 12湲곌뿉꽌뒗 B-FCM踰 寃곌낵留뚯쓣 蹂닿퀬븯떎. 2李⑥뿉뒗 T꽭룷 援먯감떆뿕뿉뒗 珥 48湲곌씠, B꽭룷 援먯감떆뿕뿉뒗 珥 33湲곌씠 李몄뿬븯떎. 쟾泥댁쟻쑝濡 30湲곌씠 T-CDC-Direct踰, T-CDC-AHG踰뺢낵 T-FCM踰뺤쓣 紐⑤몢 떆뻾븯怨, 14湲곌씠 T-CDC-Direct踰뺢낵 T-CDC-AHG踰뺤쓣 떆뻾 蹂닿퀬븯떎. 몢 湲곌 T-CDC-AHG踰뺢낵 T-FCM踰뺤쓣 떆뻾븯怨 媛곴컖 1湲곌뵫 T-CDC-Direct踰뺢낵 T-FCM踰 寃곌낵留뚯쓣 蹂닿퀬븯떎. B꽭룷 援먯감떆뿕쓽 寃쎌슦 10湲곌뿉꽌 B-CDC-Direct踰뺢낵 B-FCM踰뺤쓣, 7湲곌뿉꽌뒗 B-CDC-Direct踰뺤쓣, 洹몃━怨 12湲곌뿉꽌뒗 B-FCM踰 寃곌낵留뚯쓣 蹂닿퀬븯떎. 洹몃윭굹 T꽭룷뿉꽌 1湲곌怨 B꽭룷뿉꽌 4湲곌씠 寃곌낵瑜 엯젰븯吏 븡븯떎. 媛 꽭룷 寃궗踰뺤뿉 뵲瑜 寃곌낵瑜 Table 6뿉 젙由ы븯뒗뜲, 젙꽦寃곌낵뿉 뵲씪 寃곌낵 뙋젙쓣 떆뻾븯쑝硫, 諛섏젙웾 씗꽍諛곗닔 寃곌낵뒗 湲곌 媛꾩쓽 寃곌낵 遺꾪룷瑜 뙆븙븯湲 쐞븯뿬 븿猿 몴湲고븯떎. IX-18-01+IX-18-03 T-CDC踰뺢낵 IX-18-05+IX-18-07 T-CDC B-CDC踰 寃곌낵뒗 媛곴컖 뜑 誘쇨컧븳 寃궗씤 T-FCM怨 B-FCM踰 寃곌낵뿉꽌 80% consensus뿉 룄떖븯吏 紐삵븯뿬 Code 505瑜 쟻슜븯뿬 뙋젙 젣쇅븯怨, 洹 쇅뒗 媛 寃궗踰 궡뿉꽌 80% consensus뿉 룄떖븯吏 紐삵븯뿬 뙋젙 젣쇅븯떎. 媛 援먯감떆뿕 寃泥댁뿉꽌 遺쟻빀 寃곌낵쓽 鍮꾩쑉 Code 505뿉 빐떦븯뒗 寃곌낵뱾쓣 젣쇅븯怨 룄異쒗븯뒗뜲, 1李 T꽭룷 援먯감떆뿕뿉꽌뒗 0%-7.3% (룊洹, 2.7%; 10/372), B꽭룷 援먯감떆뿕뿉꽌뒗 0%-17.4% (룊洹, 5.4%; 7/130)씠뿀쑝硫, 2李 T꽭룷 援먯감떆뿕뿉꽌뒗 0%-4.8% (룊洹, 3.6%; 12/330), B꽭룷 援먯감떆뿕뿉꽌뒗 0%-17.5% (룊洹, 6.6%; 8/120)씠뿀떎.

Table 6 . Methods and results of human leukocyte antigen crossmatching.

TrialSpecimen MethodsTotalNegativePositive1:11:21:41:81:161:32>1:32 Intended response
1stIX-18-01+IX-18-03T-CDC-Direct45450Code 505
T-CDC-AHG453872311Code 505
T-FCM342311Code 505
B-CDC-Direct1912722111Code 505
B-FCM23419Positive
IX-18-01+IX-18-04T-CDC-Direct4542312Negative
T-CDC-AHG4541413Negative
T-FCM34322Negative
B-CDC-Direct192171493Positive
B-FCM23023Positive
IX-18-02+IX-18-03T-CDC-Direct4504532112252Positive
T-CDC-AHG450452272311Positive
T-FCM34034Positive
B-CDC-Direct190192134Positive
B-FCM23023Positive
IX-18-02+IX-18-04T-CDC-Direct45450Negative
T-CDC-AHG45450Negative
T-FCM34331Negative
B-CDC-Direct1911813211Code 505
B-FCM23122Positive
2ndIX-18-05+IX-18-07T-CDC-Direct45450Code 505
T-CDC-AHG464511Code 505
T-FCM34277Code 505
B-CDC-Direct18117313Code 505
B-FCM22616Code 505
IX-18-05+IX-18-08T-CDC-Direct4554038825113Positive
T-CDC-AHG4614534471512Positive
T-FCM34034Positive
B-CDC-Direct18018121104Positive
B-FCM22022Positive
IX-18-06 +IX-18-07T-CDC-Direct4531147421Code 505
T-CDC-AHG46442611106351Positive
T-FCM34034Positive
B-CDC-Direct18414234113Positive
B-FCM22319Positive
IX-18-06+IX-18-08T-CDC-Direct454411Negative
T-CDC-AHG464511Negative
T-FCM34340Negative
B-CDC-Direct181711Negative
B-FCM22211Negative

Abbreviations: T-CDC, T cell-complement dependent cytotoxicity; AHG, anti-human globulin; FCM, flow cytometry; B-CDC, B cellcomplement dependent cytotoxicity..


5. 議곗쭅쟻빀꽦 빆泥닿궗

媛 쉶李⑤떦 2媛쒖쓽 삁泥쓣 諛곗넚븯뿬 珥 4媛쒖쓽 臾쇱쭏뿉 븳 寃곌낵瑜 뼸뿀떎. 議곗쭅쟻빀꽦 빆泥닿궗뒗 꽑蹂꾧낵 룞젙 紐⑤몢 Immucor Lifecodes궗(Stamford, CT, USA) One Lambda궗(Canoga Park, CA, USA)쓽 luminex microbead array 湲곕컲쓽 떆빟쓣 궗슜븯뿬 씠猷⑥뼱吏怨 엳뿀떎.

꽑蹂꾧궗쓽 寃쎌슦 1李⑥뿉 20湲곌怨 2李⑥뿉 19湲곌씠 쉶떊븯뒗뜲, 紐⑤몢 쟻빀븳 寃곌낵瑜 蹂닿퀬븯떎(Table 7). 룞젙寃궗쓽 寃쎌슦뿉뒗 뿬윭 媛쒖쓽 빆썝씠 븳 鍮꾨뱶뿉 遺李⑸릺뼱 엳뒗 떆빟쓣 씠슜븳 몴쁽삎(phenotyping) 寃궗 븳 媛쒖쓽 빆썝씠 븳 鍮꾨뱶뿉 遺李⑸릺뼱 엳뒗 떆빟쓣 씠슜븳 떒씪빆썝삎 룞젙(single antigen identification) 寃궗寃곌낵瑜 1李⑥뿉꽌뒗 媛곴컖 12媛쒖 22媛쒖쓽 湲곌뿉꽌(Tables 8, 9), 2李⑥뿉꽌뒗 媛곴컖 11媛쒖 22媛쒖쓽 湲곌뿉꽌(Tables 10, 11) 蹂닿퀬븯떎. 빆썝 룞젙寃궗뿉 빐꽌뒗 젙꽦寃곌낵濡 룊媛븯怨, %PRA (percent reactive antibody) 룞젙빆썝꽦뿉 빐꽌뒗 룊媛븯吏 븡븯떎. 遺쟻빀 뙋젙쓣 諛쏆 湲곌 뾾뿀쑝굹 룞씪븳 떆빟쓣 궗슜븯뒗 湲곌뱾 궡뿉꽌룄 蹂닿퀬븳 빆썝꽦 諛 빆썝쓽 닔뒗 떎뼇븯쑝硫, %PRA쓽 蹂닿퀬踰붿쐞룄 留ㅼ슦 꼻뿀떎. 삁瑜 뱾뼱 IHA-18-02 class I쓽 寃쎌슦 4%-95%PRA쓽 遺꾪룷瑜 蹂댁뒗뜲, 洹 븞뿉꽌 룞씪븳 빆썝꽦쓣 蹂닿퀬븯硫댁꽌룄 %PRA뒗 떎瑜 湲곌뱾씠 議댁옱븯떎.

Table 7 . Kits and results of human leukocyte antigen antibody screening.

Manufacturers/kits1st2ndIntended response


IB27-18-01IB27-18-02IB27-18-03IB27-18-04




PresentPresentPresentPresent
One Lambda LABScreen Mixed11111111Present
Lifecodes LifeScreen Deluxe9988Present
Total20201919

The kis were from the following companies: One Lambda (Canoga Park, CA, USA) and Immucor Lifecodes (Stamford, CT, USA)..


怨좎같

議곗쭅쟻빀꽦寃궗 떊鍮숇룄議곗궗뒗 븳엫긽젏궗젙룄愿由ы삊쉶뿉꽌뒗 2018뀈룄뿉 泥섏쓬쑝濡 룄엯, 떆뻾릺뿀떎. 湲곗〈 븳吏꾨떒寃궗쓽븰쉶뿉꽌 떆뻾빐 솕뜕 떊鍮숇룄議곗궗쓽 踰붿쐞 諛 엯젰諛⑹떇쓣 븳엫긽寃궗젙룄愿由ы삊쉶쓽 李⑥꽭쟾궛떆뒪뀥뿉 諛섏쁺븯떎. 洹몃윭굹 寃곌낵 遺꾩꽍諛⑸쾿 諛 諛⑺뼢 洹몃━怨 蹂닿퀬꽌 뼇떇뿉 엳뼱꽌뒗 李⑥꽭쟾궛떆뒪뀥씠 媛吏 젙삎솕맂 諛⑹떇쑝濡 씤븯뿬 洹멸컙 떆뻾빐 솕뜕 諛⑹떇怨쇰뒗 긽떦븳 李⑥씠媛 엳뿀怨, 씠濡 씤빐 李몄뿬湲곌뿉꽌 蹂닿퀬꽌瑜 넻빐 옄泥 諛 李몄뿬湲곌뱾쓽 寃곌낵瑜 뙆븙븯怨 빐꽍븯뒗 뜲 뼱젮씠 엳뿀떎.

議곗쭅쟻빀꽦寃궗 봽濡쒓렇옩 李몄뿬 諛 쉶떊湲곌 1李⑥ 2李④ 룞씪븯吏뒗 븡븯떎. 2李⑥뿉꽌 HLA 삎蹂꾧궗 以 怨좏빐긽룄 寃곌낵 蹂닿퀬湲곌씠 2援곕뜲 뒛뼱궗쑝硫, HLA-B27삎 寃궗뒗 4援곕뜲 뒛뼱궗떎. B꽭룷 援먯감떆뿕쓽 寃쎌슦뿉룄 蹂닿퀬湲곌씠 2湲곌 利앷븯쑝굹 4湲곌뿉꽌 not available (NA)濡 엯젰븯뿬 떎젣 遺꾩꽍寃곌낵 닔뒗 2李⑥뿉꽌 媛먯냼븯떎.

HLA 삎쓣 湲곗닠븯뒗 諛⑹떇 2010뀈 媛쒖젙맂 World Health Organization (WHO) nomenclature 몴湲곕쾿뿉 뵲瑜몃떎[3]. Lee Park [4] 븳援씤쓽 HLA 由쎌쑀쟾옄瑜 以묒떖쑝濡 깉 紐낅챸踰뺤쓣 돺寃 쟻슜븷 닔 엳룄濡 씠瑜 媛꾩텛젮 蹂닿퀬븳 諛 엳떎. HLA 삎蹂꾧궗 寃곌낵 以 옒紐삳맂 삎쓣 蹂닿퀬븳 寃쎌슦뒗 떒 븳 嫄댁씠뿀쑝硫 삤엳젮 몴湲곕쾿쓽 삤瑜섍 4嫄 엳뿀떎. 怨좏빐긽룄 寃곌낵 以 HLA-C 由쎌쑀쟾옄 몴湲 떆 臾몄옄 C留뚯쓣 궗슜븯뒗 떊 삁泥삎怨 媛숈 Cw濡 몴湲고븳 寃쎌슦媛 2嫄, HLA-DR 由쎌쑀쟾옄 몴湲 떆 몴쟻 쑀쟾옄遺쐞씤 beta-chain쓣 몴湲고븯뒗 DRB1 떊 삁泥삎怨 媛숈 DR濡 몴湲고븳 寃쎌슦媛 2嫄 엳뿀떎. HLA-C 삁泥삎쓽 寃쎌슦 떎닔쓽 湲곌뿉꽌 C*03:04C*03:03瑜 Cw9 Cw10쑝濡 援щ텇븯吏 븡怨 broad specificity씤 Cw3쑝濡 蹂닿퀬븯떎. 씠뒗 씪遺 PCR-SSP 떆빟뿉꽌 씠 몢 삁泥삎쓣 援щ텇븷 닔 뾾뼱꽌씤 寃껋쑝濡 깮媛곷릺硫, 삁泥삎怨 빐긽룄 쑀쟾옄삎 寃곌낵媛 꼸由 씠슜릺怨 엳뒗 옣湲곗씠떇遺꾩빞뿉꽌뒗 HLA-C쓽 엫긽쟻 以묒슂꽦씠 궙븘 씠瑜 援щ텇븯뿬 蹂닿퀬븯吏 紐삵븯뒗 寃껋씠 寃궗떎쓽 닔뻾뒫젰뿉 誘몄튂뒗 쁺뼢 誘몃명븷 寃껋쑝濡 깮媛곷맂떎. IHL-18-02 IHL-18-03 C*14:02瑜 媛吏 寃泥댁씤뜲, HLA Dictionary 2008 (https://www.ebi.ac.uk/cgi-bin/ipd/imgt/hla/get_dictionary.cgi)뿉 뵲瑜대㈃ WHO뿉꽌 젙븳 삁泥삎(WHO assigned type)씠 寃곗젙릺뼱 엳吏 븡쑝硫 쟾臾멸뱾씠 젙븳 삁泥삎(expert assigned type) Cw1 삉뒗 blank濡 젣븞릺怨 엳떎. 엯젰 떆 젙빐吏 삁泥삎씠 뾾뒗 寃쎌슦 other濡 몴湲고븯룄濡 븯뒗뜲, 떎닔쓽 湲곌 other 삉뒗 blank濡 蹂닿퀬븯쑝굹 씪遺뒗 Cw14濡 蹂닿퀬븯쑝硫 1湲곌留뚯씠 Cw1濡 蹂닿퀬븯떎.

Table 8 . Methods and results of human leukocyte antigen class I and II antibody identification of IHA-18-01.

Tests/manufacturersIHA-18-01

%PRASpecificity
Class I phenotyping (n=12)
 One Lambda LABScreen PRA class I (n=5)89A2/A68/A69/B18/B35/B37/B46/B49/B50/B51/other
80A2/A68/B35/A34/A33/A26/B55/Cw8/A80/B51/B71/B52/Cw9/B72/Cw12/B18/Cw2/B50/B67/B78/B54/B65/B57/B53/B75/B62/B58/B39/B63/B38/B64/B56/B49/A69
80A2/B35/B58/A68/B51/B63/B57/B52/B72/B78/A34/A33/B18/B75/B38/B67/B71/B53/B62/A69/B49/B50/B39
80A2/B58/B72/B35/B78/A68/B57/B75/B71/B51/B53/other
78Other
 Immucor Lifecodes class I ID (n=7)100A2/B53/B35/B78/B75/B71/B77/B57/B51/B58/B49/B50/B62/B63
100Other
100B75/B62/B35/A2/B49/B78/B71/B63/B53/B56/B50/B57/A68/A3/A69/B72/B51/B55/B58/B52/B77
98Cw6/Cw10/A1/Cw8/A30/B39/A34/Cw16
94A2/A3/A30/A33/A68/B52/Cw1/Cw6/Cw15/Cw8/Cw16
92A2/B35/A69/B78/B51/A68/B53
80A2/A3/A30/A68/B13/B35/B52/B54/B56/B57/B58/B60/Cw15
Class I single antigen (n=22)
 One Lambda LABScreen single antigen class I (n=12)100A2/B51/B35/B78/B53/B71/B75/A69/B58/A68/B57/B49/B52/B77/B72/B18/B50/B62/B63/B56/B46/B37/B64/B8/B65/Cw9/B48/B76/Cw10/B5CREG (Rodey)/B8CREG (Rodey)
100B58/B71/B78/B51/B57/B75/B53/B52/B49/B72/B35/A2/B62/A68/B50/B18/B77/A69/B63/B56/B46/B37/B64/B65/B8/Cw9/B76/Cw10/B48/B54/B59/B38/B39/B45/A36/B44/A29/A74/A31/A11/A33/Cw15/Cw4/Cw6/Cw16/Cw8
100A2/A3/A11/A29/A31/A33/A36/A68/A69/A74/B8/B18/B35/B37/B38/B39/B44/B45/B46/B48/B49/B50/B51/B52/B53/B54/B56/B57/B58/B59/B62/B63/B64/B65/B71/B72/B75/B76/B78/B77/Cw2/Cw4/Cw6/Cw9/Cw10/Cw14/Cw15/Cw16/other
100A2/A3/A11/A29/A30/A31/A33/A36/A68/A69/A74/B8/B18/B35/B37/B38/B39/B44/B45/B46/B48/B49/B50/B51/B52/B53/B54/B56/B57/B58/B59/B62/B63/B64/B65/B71/B75/B76/B77/B78/Cw4/Cw9/Cw10/Cw15
100A2/A3/A11/A29/A30/A31/A33/A36/A68/A69/A74/Cw4/Cw9/Cw10/B8/B18/B35/B37/B38/B39/B44/B45/B46/B48/B49/B50/B51/B52/B53/B54/B56/B57/B58/B59/B62/B63/B64/B65/B71/B72/B75/B76/B77/B78
100A2/A68/B57/B51/A33/A29/B44/A11/Cw10/B75/Cw4/B46/B60/B49/B38/A74/B76/B41/B54/Cw16/B8/A69/B48/B35/B62/B53/Cw12/Cw7/B77/Cw6/B37/Cw9/B18/A3/B65/B56/A36/A43/B59/Cw2/B52/B39/B64/Cw14/B78/B58/Cw5/Cw8/B72/B63/A32/B73/B71/A31/Cw15/B45/Cw1/B50/B13/A66/A34/A30/A2403
100Cw10/B76/B65/Cw9/B8/B64/A2/B37/B35/A68/B46/B51/A69/B78/B53/B71/B75/B72/B62/B77/B56/B18/B63/B50/B52/B57/B49/B58/Cw15/A30/B44/A31/A11/B45/A33/A74/A29/A36/B39/B59/B38/B48/B54/B27/B47/A80/A24/A66/B61/B41/B60/A32/Cw5/B73/A34/Cw12/Cw7/Cw8/Cw14/Cw2/Cw16/Cw6/B13/Cw4/other
100A2/A68/A69/B18/B35/B37/B46/B49/B50/B51/B52/B53/B56/B57/B58/B62/B63/B71/B72/B75/B77/B78/B8/B38/B39/B45/B48/B54/B59/B64/B65/A3/A11/A29/A31/A33/A36/A74/B44/Cw4/Cw6/Cw8/Cw15/Cw16/Cw9/Cw10/B76
82A2/A34/B51/A29/B44/A66/Cw10/B57/B75/A33/A11/A68/Cw1/B77/B62/Cw14/A1/B45/Cw7/Cw8/A74/Cw4/Cw5/B38/A43/B39/B56/B41/A69/A32/B71/B72/Cw16/B53/B54/B73/B18/Cw12/A36/Cw15/Cw6/B37/B48/B49/B50/B78/B52/Cw9/Cw2/B35/B60/B63/B64/B65/A3/B8/B46/A31/B58/B59/B61/B76/B13/A30/A24
59A2/B51/B78/B35/B71/B49/B50/B72/B53/B57/B62/A68/B52/B58/B56/B18/B75/B63/B77/B37/B64/A69/B65/B46/B8/B76/Cw9/B59/B54/Cw10/B48/A36/B39/A3/A11/A29/B45/A33/B38/Cw4/A74/A31/B44/Cw8/Cw7/Cw6
58B49/B57/B50/B63/B56/B18/B58/B52/B62/A69/B77/B72/B46/B75/B71/A68/B53/B37/B78/B64/B8/B51/B35/B65/B76/Cw9/A2/Cw10/B48/B54/B59/B38/B39/A36/A29/A3/A11/A74/A33/B45/A31/B44/A30/Cw4/Cw15/Cw8
31A2/B51/B35/B75/B78/B53/B49/B71/B57/B50/B58/B56/A68/B72/B77/B52/B62/B63/A69/B18/B64/B65/B37/B8
 Immucor Lifecodes LSA class I (n=10)99A2/A3/A11/A29/A33/A36/A43/A68/A69/B8/B18/B35/B37/B38/3901/B46/B49/B50/B51/B52/B53/B54/B56/B57/B58/B59/B62/B63/B64/B65/B71/B72/B75/B76/B77/B78/Cw9/Cw10
98A2/A11/A203/A29/A3/A33/A36/A43/A68/A69/B18/B35/B37/B38/3901/B45/B46/B49/B50/B51/B52/B53/B54/B56/B57/B58/B59/B62/B63/B64/B65/B71/B72/B75/B76/B77/B78/B8/other
97A2/B35/B57/B71/B75/B49/B50/B58/B62/B51/B56/B72/A68/B52/A69/B18/B46/B37/B64/A11/A33/B54/B8/B76/B65/B59/A3/B38/A29
96A2/A68/A69/B62/B75/B77/B63/B71/B35/B49/B50/B51/B53/B56/B57/B78
82A2/A203/B53/B35/B78/B75/B71/B51/B49/B57/B50/B77/B62/B63/B58/B52/B72/B56/A68/A69
50A2/B35/B71/B75/A68/B57/B51/A69/B62/B49/B72/B50/B52/B58/B56/B18/A11/B46/B37/A3/B64/B65/B54/B8/A29/B15/B38/B59/A32/A2403/A33/3901/Cw10/other
50A2/A203/B35/B49/B57/B71/B51/B75/B53/B63/B78/B77/B72/B50/B58/B52/B56/B62/A68/A69/B18/B37/B46/B64/A11/B54/A33/B76/B65/B8/B59/A36/Cw10/Cw9/B38/3901/A43/A29/A32/A74
47A2/A11/A68/A69/A203/B18/B35/B37/B46/B49/B50/B51/B52/B56/B57/B58/B62/B63/B71/B72/B77/B78/B54/B64/B65
46A2/A203/B35/B53/B78/B57/B75/B77/B71/B50/B51/B52/B49/B62/B58/B63/B72/B56/A69/A68/B18/B46/B37/B64/A33/A11/B8/B54/B65/B59/B76/Cw10/Cw9/A36/B38/3901/A29/A43
43A2/B53/B35/A203/B78/B71/B57/B51/B77/B75/B49/B50/B58/B63/B72/B62/B52/B56/A68/A69/B18/B37/B46/B64/A33/A11/A36/B38/A29/A43
Class II phenotyping (n=12)
 One Lambda LABScreen PRA class II (n=5)97DR14/DR52/DQ4/DQ5/DQ6/DQ7/other
97DQ5/DQ7/DQ6/DQ2/DQ9/DR12/DR18/DR11/DR16/DR52/DR14/DR15/DR1/DR51/DR17/DR13/DR53/DR103
97DR13/DR17/DR11/DR12/DR14/DR18/DQ7/DQ5/DQ6
94Other
91DR7/DR15/DQ9/DR53/DR51/DR12/DR9/DQ2/DQ8/DR52/DQ4/DR4/DR8/DR16/DR1/DQ5/DR14/DR13/DR17/DR11
 Immucor Lifecodes class II ID (n=7)100DR52/DR51/DR1/DQ9/DQ2/DQ7/DQ6/DQ5/DQ4/DR4/DR8
100DR52/DR1/DR4/DR8/DQ2/DQ4/DQ5/DQ7/DQ9
100DR17/DR12/DR14/DR11/DR13/DR18
100DR14/DR17/DR11/DR12/DQ5/DR1/DR13/DQ2/DQ6/DQ7/DR16/DQ4/DR18/DR15
97Other
96DQ4/DQ2/DQ7/DQ5/DQ6
0Absent
Class II single antigen (n=22)
 One Lambda LABScreen single antigen class II (n=12)100DQ5/DQ6/DQ7/DR14/DR52/DR17/DR18/DR13/DR4/DR11
99DR14/DR52/DQ4/DQ5/DQ6/DQ7/DQ2/DR3/DR17/DR18/DR4/DR13/DR8/DR11/DR15/DR16
99DQ7/DR52/DR14/DQ6/DQ4/DQ5/DR4/DR13/DR18/DR17/DQ2/DR15/DR8/DR16/DR11/other
98DQ6/DQ4/DR14/DR15/DQ2/DR4/DQ5/DR16/DR11/DR13/DR1/DR52/DR17/DR18/DR8/DQ7/DR9
97DR14/DR52/DQ4/DQ5/DQ6/DQ7/DR1/DR4/DR13/DR17/DR18/DR11/DR15/DR16
97DQ5/DQ4/DQ6/DQ7/DR14/DR52/DR17/DR13/DR18/DR11/DR4/DR8/DR15/DR16
97DR1/DQ5/DQ4/DQ6/DQ7/DR52/DR14/DR17/DR18/DR13/DR4/DR11/DR8
97DR1/DR4/DR11/DR13/DR14/DR17/DR18/DR52/DQ4/DQ5/DQ6/DQ7/other
56DQ6/DQ7/DQ4/DR14/DR15/DQ2/DR4/DR13/DR16/DR1/DR9/DQ5/DR11/DR8/DR10/DR18/DR17/DR52
42DQ5/DQ6/DQ7/DQ4/DR52/DR14/DR17/DR1/DR18/DR4/DR13/DR11/DR8/DR15/DR16/other
39DQ4/DR14/DR52/DQ6/DQ5/DR17/DR13/DR18/DR1/DR4/DR11/DR8/DR15/DR16
28DQ4/DQ7/DQ6/DQ5/DR52/DR14/DR17/DR1/DR13/DR18/DR4/DR11
 Immucor Lifecodes LSA class II (n=10)97DR1/DR11/DR13/DR14/DR1403/DR1404/DR17/DR18/DR52/DR4/DQ4/DQ5/DQ6/DQ7/other
97DQ5/DQ6/DQ4/DR14/DQ7/DR17/DR18/DR13/DR4/DR1/DR11
97DR1/DR4/DR8/DR11/DR13/DR1404/DR1403/DR15/DR16/DR17/DR18/DR52/DQ4/DQ5/DQ6/DQ7
91DQ4/DQ5/DQ6/DQ7
83DR1/DR52/DR14/DQ5/DQ6/DR17/DR18/DR4/DR13/DQ4/DQ7/DR11/DR8/DR16
47DQ5/DQ7/DQ4/DQ6/DR1404/DR17/DR4/DR13/DR1403/DR11/other
47DR52/DR14/DR1404/DR17/DR18/DR4/DR13/DR11/DR1403/DQ2/DQ5/DQ6/DQ4/DQ9/DQ7
47DQ2/DQ6/DQ5/DQ9/DR52/DQ4/DR14/DQ7/DR1404/DR17/DR18/DR4/DR13/DR1403/DR11
47DR52/DR14/DR1404/DQ5/DQ6/DQ2/DQ9/DQ4/DQ7/DR17/DR18/DR13/DR4/DR1403/DR11
46DQ2/DQ4/DQ6/DQ7/DQ9/DR14/DR52/DR4/DR13/DR17/DR18/DQ5

Abbreviation: %PRA, percent reactive antibody. The kits were from the following companies: One Lambda (Canoga Park, CA, USA) and Immucor Lifecodes (Stamford, CT, USA)..


HLA-B27삎 寃궗뒗 떎닔쓽 湲곌 PCR 湲곕컲쓽 쟾슜 긽뭹솕 떆빟쓣 궗슜븯怨 엳뿀쑝굹, 2湲곌뿉꽌 FCM踰뺤쓣 궗슜븯怨 엳뿀쑝硫, 3湲곌 옄泥 媛쒕컻븳 遺꾩옄쑀쟾븰쟻 諛⑸쾿쓣 궗슜븯怨 엳뿀怨, other method濡 蹂닿퀬븳 湲곌 以묒뿉뒗 긽뭹솕 HLA-B typing슜 떆빟쑝濡 寃궗 썑 HLA-B27 쑀臾대 뙋젙븯뒗 湲곌룄 엳뒗 寃껋쑝濡 뙆븙릺뿀떎.

HLA 援먯감떆뿕 떆뻾湲곌뱾뿉꽌 蹂솕뒗 T-FCM踰뺤씠 T-CDC-Direct踰뺢낵 T-CDC-AHG踰 以 븳 媛吏瑜 泥댄븯嫄곕굹 B-CDC-Direct踰 떊 B-FCM踰뺣쭔쓣 떆뻾븯뒗 湲곌씠 젏李 利앷븯怨 엳떎뒗 寃껋씠떎. FCM踰뺤쓽 寃쎌슦 떆뿕 寃泥댁 쓬꽦議곕Ъ吏 媛꾩쓽 median fluorescence intensity (MFI) ratio瑜 湲곕컲쑝濡 젙꽦 뙋젙쓣 븯怨 씠瑜 諛섏젙웾 寃곌낵濡 몴湲고븯寃 릺뒗뜲, 媛 湲곌留덈떎 떎瑜 cut off瑜 媛吏怨 엳쑝硫 湲곗〈 CDC踰뺤뿉꽌 꼸由 궗슜릺뼱삩 씗꽍諛곗닔 諛섏젙웾 몴湲곗 뿰怨꾪븯뿬 寃곌낵瑜 빐꽍븯湲곌 뼱졄떎. 삉븳 湲곗〈 븳吏꾨떒寃궗쓽븰쉶 쇅遺젙룄愿由 寃곌낵뿉꽌 媛 湲곌쓽 MFI ratio瑜 遺꾩꽍븯쓣 븣 留ㅼ슦 꼻 踰붿쐞뿉 嫄몄퀜 遺꾪룷븯怨 엳쓬쓣 愿李고븯뒗뜲, 씠뒗 Yu 벑[5]씠 2015뀈 븳吏꾨떒寃궗쓽븰쉶 二쇨 HLA 援먯감떆뿕 몴以솕궗뾽쓽 씪솚쑝濡 꽕臾몄“궗瑜 넻빐 議곗궗 蹂닿퀬븳 諛붿 媛숈씠 湲곌留덈떎 떎뼇븳 議곌굔뿉꽌 쑀꽭룷 援먯감떆뿕쓣 떆뻾븯怨 엳湲 븣臾몄쑝濡 깮媛곷맂떎. 떦떆 寃궗湲곌뱾쓣 긽쑝濡 寃궗踰 썙겕닄쓣 떆뻾븯뿬 씪遺 媛쒖꽑씠 씠猷⑥뼱議뚯쑝由щ씪 湲곕릺굹 뼢썑 몴以솕맂 봽濡쒗넗肄쒖쓽 媛쒕컻 諛 쟻슜怨 媛숈 醫 뜑 쟻洹뱀쟻씤 HLA 쑀꽭룷 援먯감떆뿕 몴以솕瑜 쐞븳 끂젰씠 븘슂븯寃좊떎. 寃곌낵 뙋젙뿉 엳뼱꽌뒗 誘쇨컧룄媛 떎瑜 몢 媛吏 씠긽쓽 寃궗踰뺤쓣 諛섎뱶떆 떆뻾븯룄濡 沅뚭퀬븯怨 엳뒗 諛 誘쇨컧룄媛 넂 寃궗뿉꽌 80% 씠긽쓽 씪移섎 蹂댁씠吏 븡뒗 寃쎌슦 븯쐞寃궗쓽 寃곌낵뒗 Code 505濡 湲곗닠븯怨 뙋젙 젣쇅븯떎. 洹몃윭굹 씠뒗 College of American Pathologist 젙룄愿由ы봽濡쒓렇옩쓽 뙋젙湲곗뿉 뵲씪 誘쇨컧룄媛 넂 寃궗(T-FCM踰 삉뒗 T-CDC-AHG踰)뿉꽌 10% 씠긽쓽 뼇꽦寃곌낵瑜 蹂댁씠뒗 寃쎌슦 븯쐞寃궗뿉꽌 80% 씠긽쓽 씪移섎 蹂댁씠吏 븡뜑씪룄 뼇꽦寃곌낵뒗 뙋젙 젣쇅, 쓬꽦寃곌낵뒗 unacceptable濡 뙋젙븯뜕 湲곗〈쓽 뙋젙湲곗뿉 鍮꾪븯뿬 떊鍮숇룄議곗궗 寃곌낵뿉 븳 뙋蹂꾨젰씠 뼥뼱吏誘濡 뼢썑 뙋젙湲곗쓽 媛쒖꽑씠 씠猷⑥뼱졇빞 븯寃좊떎. 援먯감떆뿕 寃泥댁뿉꽌 遺쟻빀 寃곌낵쓽 鍮꾩쑉 T꽭룷뿉꽌 1, 2李 룊洹 3.1% (22/702)씤뜲 諛섑븯뿬 B꽭룷뿉꽌뒗 6.0% (15/250)쑝濡 넂븯쑝硫, B꽭룷 援먯감떆뿕쓽 寃쎌슦 2李⑥뿉꽌 4湲곌씠 NA濡 엯젰븯떎. 씠뒗 B꽭룷 援먯감떆뿕씠 긽쟻쑝濡 湲곌 媛 蹂씠뿉 痍⑥빟븿쓣 떆궗븯뒗뜲, 留먯큹삁븸 궡 B꽭룷 닔媛 쟻怨 遺꾨━ 떆 쉶닔쑉씠 궙쑝硫 굹씪濡 슱 而щ읆쓣 궗슜븷 寃쎌슦 異붽쟻씤 議곗옉쑝濡 깮議대룄媛 媛먯냼븷 닔 엳뒗 젏 벑쓣 怨좊젮 떆 삁긽븷 닔 엳뒗 寃곌낵씠떎. 洹몃윭誘濡 B꽭룷 痍④툒 諛 寃궗떆뻾 떆 닕젴룄媛 뜑 뼢긽릺룄濡 媛쒖꽑솢룞씠 븘슂븯寃좊떎.

Table 9 . Methods and results of human leukocyte antigen class I and II antibody identification of IHA-18-02.

Tests/manufacturersIHA-18-02

%PRASpecificity
Class I phenotyping (n=12)
 One Lambda LABScreen PRA class I (n=5)18A31/A33/A30/other
11A31/A33
9A31/A33
9A31/A33/A30/A32
9A31/A33
 Immucor Lifecodes class I ID (n=7)44A30/A31/A32/A33/A36
42A30/A31/A33/B37/B60
42A31/A33/B37/A30
40A30/A31/A33
40A30/A31/A33/B37/B60
40A31/A33/A32/A30
28A31/A33/B65/B37
Class I single antigen (n=22)
 One Lambda LABScreen single antigen class I (n=12)95A31/A33/A30/A74/A32/A36
67A30/A33/A31/B46/A36/A32/A74/B63/Cw4/Cw5/A34/A68/A66/Cw6/B8/A29/B76/other
55A29/A33/A30/A74/B76/B8/A32/A3/A36/A31/B46/A66
49A31/A30/A33/A32/A74
49A31/A33/A30/A74/A32
49A31/A30/A33/A32/A74/other
49A30/A31/A32/A33/A36/A74/other
46A31/A33/A30/A74/A32/A36
12A31/A33/A30/A74/A32/A36/B8/B46/A29
8A31/A33/A30/A74/A32
8A31/A33/A30/A32/A74/other
7A31/A33/A30/A32/A36/A74
 Immucor Lifecodes LSA class I (n=10)49A30/A31/A32/A33/A36
49A30/A31/A32/A33
48A30/A31/A33
48A31/A33/A30
47A31/A33/A30/A32/A36/A74
7A31/A33/A30/A32/A36/A74
7A31/A33/A30/A32/B37/Cw7
6A31/A33/A30/A32/A36
6A31/A33/A30/A32/A36
4A31/A33/A30
Class II phenotyping (n=12)
 One Lambda LABScreen PRA class II (n=5)94DR8/DR12/DR51/DQ6/DQ7/DQ8/DQ9/other
94DQ7/DQ2/DQ6/DQ9/DQ8/DR12/DR8/DR11/DR51/DR15/DR52/DR13/DR7/DR53/DR16/DR9
94DR8/DR12/DQ8/DQ7/DR51/DQ9/DQ6/DR13/DR16/DR11/DR7/DR4/DR15/other
86Other
46DR8/DR12/DR11/DQ9/DQ6/DQ8/DR13/DR15/DR16
 Immucor Lifecodes Class II ID (n=7)100Other
97DR51/DR13/DR17/DR12/DQ9/DR8/DQ4/DQ6/DR10/DQ2/DR103/DR7/DQ7/DQ8
97DR8/DR7/DR9/DR52/DR51/DR103/DQ4/DQ6/DQ7/DQ8/DQ9/DQ2
97DQ8/DQ9/DR8/DQ6/DR13/DR14/DR15/DR16
97DR8/DR103/DR13/DQ9/DR12/DR16/DQ8/DQ6/DQ4/DR7/DQ7/DR11/DR14/DQ2/DR15
75DQ6/DR8/DQ8/DQ9
30DR8/DQ8/DQ9
Class II single antigen (n=22)
 One Lambda LABScreen single antigen class II (n=12)98DR8/DR12/DR51/DQ6/DQ7/DQ8/DQ9/DR103/DR4/DR7/DR11/DR13/DR16/DR15/DQ2/DQ4/DR9
98DR8/DR12/DR51/DQ7/DQ8/DQ9/DR13/DQ6/DR16/DR11/DR103/DR7/DR4/DQ2/DR15/DQ4
98DQ6/DQ7/DQ4/DQ8/DQ9/DR15/DR12/DR11/DR16/DR13/DQ2/DR103/DR7/DR8/DR9/DR51/DR4
98DQ7/DR51/DQ6/DQ9/DQ8/DR8/DR12/DQ2/DR4/DR7/DR103/DR11/DR16/DR13/DR9/DQ4/DR15/other
97DR8/DR12/DQ8/DQ9/DQ6/DR51/DQ7/DR13/DR16/DR11/DR103/DR7/DR4/DR15
97DR4/DR7/DR8/DR11/DR12/DR13/DR15/DR16/DR51/DQ6/DQ7/DQ8/DQ9/other/DR103
95DQ9/DQ6/DQ8/DR12/DQ7/DR16/DR13/DR11/DR7/DR103/DR15
92DR8/DR12/DR51/DQ6/DQ7/DQ8/DQ9/DR7/DR11/DR13/DR16/DR15
49DQ6/DQ7/DQ4/DQ9/DQ8/DR15/DQ2/DR9/DR13/DR11/DR16/DR12/DR8/DR17/DR103/DR7/DR51
39DR8/DR12/DQ8/DQ9/DQ6/DR51/DQ7/DR13/DR16/DR11/DR103/DR7/DR4/DR15
39DR8/DR12/DQ8/DQ7/DR51/DQ9/DQ6/DR13/DR16/DR11/DR7/DR4/DR15/other
34DQ6/DQ9/DQ8/DR8/DR12/DR13/DR51/DR16/DQ7/DR11/DR7/DR4
 Immucor Lifecodes LSA class II (n=10)100DR4/DR7/DR8/DR11/DR12/DR13/DR1404/DR1403/DR15/DR16/DR17/DR51/DR103/DQ6/DQ7/DQ8/DQ9
98DQ8/DQ6/DR8/DQ9/DR14/DR12/DR11/DR7/DR16/DR13/DQ7/DR4/DR1/DR15
98DR1/DR12/DR14/DR8/DR13/DR11/DR16/DR51/DQ6/DR7/DR4/DQ9/DQ8/DR15/DQ7/DR17
97DQ6/DQ7/DQ8/DQ9/DR103/DR11/DR12/DR13/DR1403/DR1404/DR15/DR16/DR4/DR51/DR7/DR8
82DR8/DR12/DQ6/DQ8/DQ9
40DQ8/DR8/DQ9/DQ6/DR12/DR1404/DR13/DR11/DR1403/DR51/DR16/DR7/DQ7/DR4/DR103/DR15
39DR8/DR1404/DR12/DQ8/DQ6/DQ9/DR11/DR1403/DR7/DR16/DR4/DR13/DQ7/DR15/other
39DR8/DR1404/DR12/DR11/DR13/DR7/DR1403/DR16/DR51/DR4/DR103/DR15/DQ8/DQ6/DQ9/DQ7
39DR8/DR12/DR1404/DQ6/DQ8/DQ9/DR11/DR13/DR16/DR1403/DQ7
39DR8/DR12/DR1404/DQ8/DQ6/DR13/DQ9/DR1403/DR11/DR16/DR7/DR51/DR4/DR103/DQ7/DR15

Abbreviation: %PRA, percent reactive antibody. The kits were from the following companies: One Lambda (Canoga Park, CA, USA) and Immucor Lifecodes (Stamford, CT, USA)..


Table 10 . Methods and results of human leukocyte antigen class I and II antibody identification of IHA-18-03.

Tests/manufacturersIHA-18-03

%PRASpecificity
Class I phenotyping (n=11)
 One Lambda LABScreen PRA class I (n=4)9B13
9B13
7B13/B27/B60
7B13/B27/B47
 Immucor Lifecodes class I ID (n=7)32B7/B13/B60/B61/B81/B47/B44
32B13/B7/B60/B61/B81/B47/B44
32B7/B13/B44/B47/B60/B61/B81
32B13/B7/B60/B61/B47/B81/Bw4/B44
32B13/B44/B61/B7/B60/B81/B47
28B13/B60/B61/B7/B47/B81
28B7/B13/B47/B60/B61/B81
Class I single antigen (n=22)
 One Lambda LABScreen single antigen class I (n=12)96B13/B81/B7/B48/B44/B61/B60/B27/B38/B47/B63/B59/B57/B49/B77/B52/B37/B51
94B13/B7/B27/B44/B48/B60/B61/B81/A24/A29/B37/B38/B46/B47/B49/B51/B52/B53/B57/B58/B59/B63/B77
94B13/B48/B7/B61/B60/B27/B38/B44/B47/B59/A24/B63/B57/B49/B58/B37/B52/B51/B46
88B13/B7/B27/B44/B48/B60/B61/B81/A24/B37/B38/B47/B49/B51/B52/B57/B59/B63/B77
87A24/B61/B51/B44/B27/B57/B13/B60/B73/B48/B46/A23/B77/B37/B58/B7/B53/B49/Cw2/B47/B52/B81/B59/B63/B38/B76
83B37/A24/B13/B59/B7/B81/B44/B27/B60/B61/B38/B47/B48/B57/B63
79B13/B81/B7/B48/B61/B60/B44/B27/B38/B47/B63/B57/B37/B77/B58/B59/B49/B52
63B13/B7/B44/B81/B61/B27/B60/B38/B63/B47/B59/B49
60B13/B7/B61/B60/B44/B27/B47
29B13/B44/B7/B27/B81/A24/B61/A23/B60/B63/Cw2/B49/B37/B47/B76
21B13/B81/B7/B61/B48/B60/B44/B27/B38/B47/B63/B57/B59/B49/B77/B52
20B13/B7/B81/B44/B61/B27/B60/B48/B38/B47/B59/B63/B49/B57/A24
 Immucor Lifecodes LSA class I (n=10)88B13/B7/B27/B60/B81/B47/B61/A23/B44/B37/B63/A24/A29/B57/B38/B48/B77/B58/B73/B59
77A23/A24/A29/B7/B13/B27/B44/B47/B60/B61/703/B81/other
73B13/A23/B7/A24/B27/A29/B47/B44/B60/B81/B63/B37
45A23/B7/B13/B27/B47/B60/B61/B81
19B7CREG (Rodey)/B13
19B13B7/B81/B61/B60/B47/B27/A23/A29/B44/B48/A24/B63/B37
16B13/B7/A23/A29/B27/B40/B47/B81/A24/B44
16B13/B7/703/B81/B60/B61/B47/B27/A23/B44/A29/B37
14A23/B7/B13/B27/B47/B60/B61
11B13/B7/A23/703/B81/B60/B61/B47/A29/B27
Class II phenotyping (n=11)
 One Lambda LABScreen PRA class II (n=4)91DR12/DR18/DR17/DR7/DR9/DR11/DR13/DR8/DR14
89DR12/DR17/DR7/DR52/DR9/DR18/DR53/DR13/DR11/DR14/DR51/DQ9/DQ2
89Other
89DR12/DR7/DR17/DR18/DR9/DR13/DR11/DR14/DR52/DR53/DR51
 Immucor Lifecodes class II ID (n=7)73DR52/DQ7/DQ2/DR7/DR9/DR8/DQ4
73DQ4/DQ7/DQ2/DR7/DR9/DR8/DR11/DR12/DR13/DR14/DR17/DR18/DR52
73DQ7/DR52/DQ4/DQ2/DR12
73DR7/DR8/DR9/DR10/DR12/DR13/DR17/DR18/DQ2/DQ4/DQ7
73DQ4/DR7/DQ2/DQ7/DR12/DR18/DR14/DR17/DR13/DR8/DR11
70DR7/DR8/DR9/DR11/DR12/DR13/DR14/DR17/DR18/DR52/DQ2/DQ4/DQ7
70DQ7/DQ4/DQ2/DR18/DR17/DR12/DR14/DR13/DR9/DR7
Class II single antigen (n=22)
 One Lambda LABScreen single antigen class II (n=12)98DR12/DR52/DR7/DR8/DR9/DR17/DR18/DR11/DR13/DR14
97DR12/DR52/DR7/DR17/DR8/DR18/DR9/DR13/DR14/DR11/DQ6/DQ7/DQ2/DQ4
96DR52/DR12/DR7/DR17/DR8/DR18/DR9/DR13/DR14/DR11/other
91DR14/DR52/DR12/DR11/DR13/DR9/DQ7/DR7/DR18/DR17/DR8/DQ2/DQ4
85DQ7/DQ2/DQ4/DR12/DR52/DR7/DR8/DR17/DR9/DR14/DR13/DR11
83DR12/DR52/DQ7/DR7/DR8/DR9/DR17/DR18/DR11/DR13/DR14
82DR9/DR12/DR52/DR8/DR7/DR17/DR18/DR13/DR14/DR11/other
82DR12/DR52/DR7/DR8/DR17/DR18/DR9/DR13/DR14/DR11
82DR12/DR52/DR7/DR8/DR17/DR18/DR9/DR13/DR14/DR11/other
25DR12/DR52/DR7/DR8/DR17/DR18/DR9/DR13/DR14/DR11
25DR12/DR52/DR7/DR9/DR8/DR17/DR18/DR13/DR14/DR11
25DR12/other/DR52/DR7/DR8/DR17/DR18/DR9/DR13/DR14/DR11
 Immucor Lifecodes LSA class II (n=10)82DR7/DR8/DR9/DR11/DR12/DR13/DR14/DR17/DR18/DR52/DR1403/DR1404/other
82DR7/DR8/DR9/DR11/DR12/DR13/DR14/DR17/DR18
82DR52/DR12/DR7/DR8/DR18/DR14/DR17/DR9/DR11/DR13
82DR52/DR12/DR8/DR7/DR9/DR14/DR18/DR17/DR13/DR11
32DQ5/DQ4/DQ6/DR12/DR3/DR1/DR7/DR8/DR9/DR14/DR2/DR13/DR1403/DR11
32DQ4/DQ7/other/DR52/DR12/DR7/DR1404/DR1403/DR9/DR8/DR18/DR17/DR11/DR13
32DQ7/DQ9/DQ2/DQ4/DR12/DR52/DR7
32DQ7/DQ9/DQ4/DR52/DR12/DQ2/DR7/DR9/DR8/DR1404/DR18/DR17/DR1403/DR13/DR11
32DR7/DR8/DR9/DR11/DR12/DR13/DR14/DR17/DR18/DR52
32DQ7/DQ9/DQ4/DR12/DQ2/DR52/DR7/DR8/DR18/DR9/DR17/DR14/DR13/DR11/DR1404

Abbreviation: %PRA, percent reactive antibody. The kits were from the following companies: One Lambda (Canoga Park, CA, USA) and Immucor Lifecodes (Stamford, CT, USA)..


HLA 빆泥 꽑蹂 諛 룞젙寃궗뒗 援궡 紐⑤뱺 湲곌뱾씠 luminex microbead array踰뺤쑝濡 떆뻾븯怨 엳떎. 援궡뿉꽌 궗슜릺怨 엳뒗 Immucor Lifecodes궗 One Lambda궗쓽 떆빟뱾 옄泥댁쟻쑝濡 뼇꽦 뙋젙湲곗쓣 젣떆븯怨 엳쑝굹 젅쟻씤 湲곗 뾾쑝硫 뙋룆옄뿉 뵲씪 CREG (cross reactive group)굹 寃泥댁쓽 듅꽦쓣 怨좊젮븯뿬 뼇꽦 뿬遺瑜 뙋젙븯寃 맂떎. 洹몃윭誘濡 쁽 떆젏뿉꽌 룞젙맂 빆썝꽦쓽 醫낅쪟굹 닔瑜 룊媛븯湲곕뒗 뼱졄떎. %PRA뒗 룞젙븳 빆썝꽦뿉 뵲씪꽌 寃곗젙릺吏留 씠瑜 룄異쒗븯湲 쐞븯뿬 뼱뼡 뜲씠꽣踰좎씠뒪瑜 湲곕컲쑝濡 뼱뼡 怨듭떇뿉 쓽븯뿬 怨꾩궛븯뒗媛뿉 뵲씪 떖씪吏 닔 엳떎. 삁瑜 뱾뼱 IHA-18-02 class I쓽 寃쎌슦 4%-95%PRA쓽 遺꾪룷瑜 蹂댁뒗뜲, 13媛 湲곌뿉꽌뒗 46% 씠긽쓽 %PRA瑜 蹂닿퀬븯怨 9媛 湲곌뿉꽌뒗 12% 씠븯쓽 %PRA瑜 蹂닿퀬븯떎. 삉븳 룞씪븳 빆썝꽦쓣 蹂닿퀬븯硫댁꽌룄 %PRA뒗 95% 7%濡, 48% 4%濡 떖由 蹂닿퀬븳 湲곌뱾씠 議댁옱븯떎. 씠뒗 븳援씤쓽 HLA 삎蹂 옄猷뚯뿉 湲곕컲븳 %calculated PRA (cPRA)瑜 룄異쒗븯吏 븡怨 떆빟 궡뿉 룷븿맂 쟾泥 鍮꾨뱶 以 뼇꽦鍮꾨뱶쓽 鍮꾩쑉留뚯쓣 怨꾩궛븯쓣 媛뒫꽦쓣 깮媛곹빐 蹂 닔 엳떎. 洹몃윭굹 洹몄 媛숈 怨꾩궛諛⑹떇 듅젙 씤援ъ쭛떒씠 媛吏 HLA뿉 븳 媛먯옉 젙룄瑜 삁痢≫븯뒗 PRA쓽 쓽誘몄뿉 쟾 留욎 븡뒗떎. 븳吏꾨떒寃궗쓽븰쉶 硫댁뿭遺꾧낵뿉꽌뒗 2015뀈 븳援씤 옄猷뚮 씠슜븯뿬 web 湲곕컲 cPRA calculator (http://cpra.inforang.com/form/form.html)瑜 留뚮뱾뿀쑝硫 씠뒗 紐⑤뱺 湲곌뿉꽌 臾대즺濡 궗슜븷 닔 엳뒗뜲, 쁽옱濡쒖꽌뒗 씠瑜 씠슜븯뿬 %PRA瑜 룄異쒗븯뒗 寃껋씠 媛옣 쟻빀븯떎怨 븷 닔 엳떎. 떆빟 媛 빆썝룞젙쓽 誘쇨컧룄뒗 룞젙맂 빆썝쓽 닔 삉뒗 %PRA瑜 씠슜븯뿬 鍮꾧탳븷 닔 엳寃좊떎. 洹몃윭굹 湲곌 媛 뙋룆湲곗 諛 %PRA 蹂닿퀬湲곗쓽 떎뼇븿쑝濡 씤븯뿬 쁽 떆젏뿉꽌뒗 뼱졄떎. 遺꾩꽍뿉뒗 룷븿릺吏 븡븯吏留 빆썝 몴쁽삎 寃궗瑜 떆뻾븯怨 엳뒗 湲곌뱾씠 1李⑥ 2李⑥뿉 媛곴컖 12 諛 11湲곌씠 엳뿀떎. 닔엯떆빟씠湲곕뒗 븯굹 %PRA瑜 룄異쒗븯怨, native 빆썝쓣 궗슜븯誘濡 옱議고빀 빆썝쓣 궗슜븯뒗 떒씪빆썝 룞젙寃궗뿉꽌쓽 臾몄젣瑜 씪遺 빐寃고븷 닔 엳떎뒗 옣젏씠 엳쑝굹 젙솗븳 빆썝꽦쓣 룞젙븯뒗 뜲뒗 븳怨꾧 엳떎.

2018뀈 泥섏쓬쑝濡 븳엫긽寃궗젙룄愿由ы삊쉶뿉 룄엯릺뼱 떆뻾븳 議곗쭅쟻빀꽦寃궗 떊鍮숇룄議곗궗뒗 寃泥댁쓽 以鍮, 諛쒖넚 諛 寃곌낵 엯젰怨쇱젙 씠쟾쓽 떊鍮숇룄議곗궗 鍮꾧탳븯뿬 닚議곕줈씠 吏꾪뻾릺뿀쑝硫, 媛 빆紐⑹뿉 븳 議곗궗寃곌낵瑜 醫낇빀빐 蹂 븣 遺遺꾩쓽 湲곌씠 留ㅼ슦 넃 떊鍮숇룄瑜 쑀吏븯怨 엳쓬쓣 솗씤븯떎. 洹몃윭굹 뼢썑 HLA 援먯감떆뿕쓽 뙋젙湲곗 諛 쟾諛섏쟻씤 蹂닿퀬꽌 뼇떇쓽 媛쒖꽑 씠猷⑥뼱졇빞 븷 寃껋쑝濡 깮媛곷맂떎.

Table 11 . Methods and results of human leukocyte antigen class I and II antibody identification of IHA-18-04.

Tests/manufacturersIHA-18-04

%PRASpecificity
Class I phenotyping (n=11)
 One Lambda LABScreen PRA class I (n=4)89A1/A36/A69/A29/A66/Cw10/A30/A11/A26/Cw14/A25/A3/A24/A34/B52/Cw15/A33/A68/A74/A80/A31/Cw16/B7/B27/Cw12/B72/B56/B35
82A1/A11/A36/A29/A66/A26/A34/A25/A69/A33/A68/A74/A80
58A1/A36/A25/A29/A66/A11/A26
40A1/A66/A36/A26/A11
 Immucor Lifecodes class I ID (n=7)92Cw6/Cw4/A1/Cw8/Cw1/A68/A30/A26/A66/B57
92Cw6/Cw7/Cw4/Cw1/A30/A26/B45
90A1/A36/A26/A66/A11/A25/A30/A34/A3/A29/A68/A74
88A1/A26/A66/A11/A33/A25/A30/A3/A29/A68
84A1/A2/A3/A11/A25/A26/A29/A30/A34/A36/A66/A68/A69/A74
84A1/A36/A11/A26
58A1/A11/A26/A29/A34/A36/B8/B27/B53/B58
Class I single antigen (n=22)
 One Lambda LABScreen single antigen class I (n=12)100A1/A36/A43/A26/A11/B76/A66/A25/A80/A29/A34/A74/A3/A68/A69/A2/Cw16/A30/Cw8/A31/Cw12/Cw7/Cw5/B73/Cw6
100A1/A26/A36/A43/A66/B76/A11/A25/A29/A34/A80/A2/A3/A30/A31/A33/A68/A69/A74/B54/B61/B73/Cw1/Cw2/Cw5/Cw6/Cw7/Cw8/Cw12/Cw14/Cw15/Cw16
100A43/A26/B76/A25/A29/A80/A66/A34/A11/A74/A68/A69/A3/A31/A30/A36/Cw16/A2/Cw7/Cw8/Cw5/Cw12/B73/Cw6/B61/Cw15/A33/Cw14/Cw1
100A2/B51/A34/B61/A66/A68/A30/A33/A11/A29/Cw7/Cw14/A43/A1/Cw8/A74/Cw4/B54/A26/A69/Cw1/Cw2/A25/Cw12/A36/B67/Cw16/Cw9/B35/B73/A3/Cw15/B46/A31/A80/B81/B76/Cw10/Cw5/Cw6
96A26/A1/A29/A11/A3/A68/A31/A2/A30/A33/B61/B67/B35/5102/B54
96A1/A26/A36/A43/B76/A11/A25/A29/A34/A66/A80/A2/A3/A68/A74/B61/B73/Cw5/Cw6/Cw7/Cw8/Cw12/Cw14/Cw16
92A43/A26/B76/A25/A29/A34/A80/A66/A11/A69/A68/A36/A74/A30/Cw16/A2/A3/A1/A31/Cw8/Cw7/Cw12/B73/Cw5/Cw6
81A1/A2/A43/A26/A25/B76/A66/A80/A34/A29/A11/A36/Cw16/A68/A74/A3/A69/A30/Cw8
77A43/A26/A66/A25/B76/A80/A36/A29/A34/A11/A1/A68/Cw16/A2/A69/A74/A30
39A26/A43/A66/A1/A36/A11/A25/B76/A34/A80/A29/A3/A30/A68/A2/A74/A31/B73/A33/A69
33A26/A43/B76/A66/A25/A36/A80/A1/A29/A34/A11/A3/A74/A2/Cw16/Cw8/A68/Cw12/Cw5/A30/Cw7/Cw6/B73/A31/A69/B61
32A43/A26/B76/A25/A36/A80/A66/A1/A29/A11/A34/Cw16/A3/A74/A68/A69/Cw8/A30/Cw7/A2/B73/Cw12/Cw5/Cw6/A31
 Immucor Lifecodes LSA class I (n=10)79A1/A2/A3/A11/A25/A26/A29/A30/A34/A36/A43/A66/A68/A69/A80/B76
79B76/A43/A11/A26/A34/A66/A29/A25/A68/A30/A3/A69/A80/A2/A1/A74
79A11/A1/A36/A26/A43/B76/A34/A66/A25/A29/A68/A3/A69/A30/A80/A2
44A1/A3/A11/A25/A26/A29/A30/A68/A69/B76
23A1/B7/A1CREG (Rodey)
23A1/A36/A11/B76/A34/A43/A26/A29/A66/A68/A80/A25/A69/A30/A3/A2/A74
22B15/A1/A36/A11/A34/A43/A26/A66/A29/A68/A80/A25/A3/A30/A69/A2
22A1/A36/A11/B76/A34/A43/A66/A29/A26/A68/A80/A25/A69/A30/A3/A2
22A1/A36/A11/B76/A34/A66/A26/A29/A68/A80/A43/A25/A30/A3/A69/A2
21A1/A3/A11/A25/A26/A29/A30/A34/A36/A43/A66/A68/A69/A80/B76
Class II phenotyping (n=11)
 One Lambda LABScreen PRA class II (n=4)94DQ6/DQ5/DQ8/DQ2/DQ4/DQ9/DR17/DR18/DR14/DR16/DR12
77DR17/DR18/DR51/DR53/DQ7/DR9/DR4/DQ8/DR7/DR12/DR8/DQ4/DQ2
54DR18/DR17/DQ5/DQ6/DR51
43Other
Immucor Lifecodes class II ID (n=7)97DR51/DQ9/DR10/DQ8/DQ4/DR103/DQ2/DQ5/DQ6/DR1/DR14
97DQ2/DQ4/DQ6/DQ5/DQ9/DR1/DR10/DR103/DR15/DR16
97DR51/DQ9/DR10/DQ8/DQ2/DQ4/DR103/DR1/DQ5/DQ6/DR14
97DQ2/DQ8/DQ9/DR15/DR16
97DR1/DR10/DR14/DR15/DR16/DR103/DQ2/DQ4/DQ5/DQ6/DQ8/DQ9
97DQ9/DQ8/DQ6/DQ5/DQ2/DQ4
57DR1/DR10/DR14/DR15/DR16/DR51/DR103/DQ2/DQ4/DQ5/DQ6/DQ8/DQ9
Class II single antigen (n=22)
 One Lambda LABScreen single antigen class II (n=12)100DQ5/DQ9/DQ8/DQ2/DQ4/DR16/DQ6/other
100DQ9/DQ5/DQ4/DQ8/DQ2/DR52/other
100DQ2/DQ5/DQ6/DQ8/DQ9/DQ4/DR16/DR52
100DQ8/DQ9/DQ2/DQ6/DQ5/DQ4/DQ7
100DR7/DR52/DR16/DQ4/DQ2/DQ8/DQ9/DQ6/DQ5
98DQ8/DQ9/DQ2/DQ4/DQ6/DQ5/DR16
98DQ8/DQ9/DQ2/DQ6/DQ4/DR16/DQ5/other
98DQ5/DQ6/DQ8/DQ9/DQ2/DQ4/DR52
93DQ8/DQ9/DQ2/DQ4/DR16/DR52
24DQ5/DQ6/DQ2/DQ9/DQ8/DQ4
23DQ8/DQ9/DQ2/DQ4/DR16/DQ6/DQ5
22Other/DQ8/DQ9/DQ2/DQ4/DR16/DQ6/DQ5
 Immucor Lifecodes LSA class II (n=10)93DQ2/DQ5/DQ6/DQ8/DQ9/other
91DQ2/DQ4/DQ6/DQ8/DQ9
81DQ2/DQ8/DQ9/DQ7/DQ4
67DQ8/DQ9/DQ2/DQ4
33DQ2/DQ4/DQ5/DQ6/DQ8/DQ9
33DQ2/DQ8/DQ6/DQ9/DQ5/DR4
33DQ6/DQ5/DQ8/DQ2/DQ9/DQ4/DQ7
33DQ6/DQ5/DQ8/DQ2/DQ9/DQ4/DQ7
32DQ2/DQ3/DQ4/DQ6/DQ1/DQ5
24DQ2/DQ4/DQ5/DQ6/DQ8/DQ9

Abbreviation: %PRA, percent reactive antibody. The kits were from the following companies: One Lambda (Canoga Park, CA, USA) and Immucor Lifecodes (Stamford, CT, USA)..


媛먯궗쓽 湲

젙룄愿由щЪ吏덉쓽 젣議곗뿉 룄쓣 二쇱떊 諛뺤슦 꽑깮떂怨 硫댁뿭寃궗떎 꽑깮떂뱾 洹몃━怨 뿄삁떎 젙삙寃, 源삙誘 媛꾪샇궗 諛 젙誘몄젙 뿰援ъ썝뿉寃 媛먯궗쓽 쑜쓣 쟾븳떎.

References
  1. Park MH. A questionnaire survey of HLA laboratories in Korea (1993). J Korean Soc Transplant 1993;7:245-8.
  2. Park MH, Whang DH, Kim BC. Two-year study on the HLA typing proficiency survey in Korea, 1996-1998. Korean J Clin Pathol 1999;19:714-22.
  3. Marsh SG, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA, et al. Nomenclature for factors of the HLA system, 2010. Tissue Antigens 2010;75:291-455.
    Pubmed KoreaMed CrossRef
  4. Lee KW, Park MH. New HLA nomenclature (2010) and its clinical application in Koreans. Korean J Lab Med 2010;30:203-17.
    Pubmed CrossRef
  5. Yu S, Kang ES, Park MH. A questionnaire survey of HLA crossmatch tests in Korea (2015). Lab Med Online 2017;7:147-56.
    CrossRef